CO2018008759A2 - Inhibidores de mcl-1 y métodos de uso de los mismos - Google Patents
Inhibidores de mcl-1 y métodos de uso de los mismosInfo
- Publication number
- CO2018008759A2 CO2018008759A2 CONC2018/0008759A CO2018008759A CO2018008759A2 CO 2018008759 A2 CO2018008759 A2 CO 2018008759A2 CO 2018008759 A CO2018008759 A CO 2018008759A CO 2018008759 A2 CO2018008759 A2 CO 2018008759A2
- Authority
- CO
- Colombia
- Prior art keywords
- methods
- mcl
- inhibitors
- tridecaeno
- pentaazaheptacyclo
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D497/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D497/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D515/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662326156P | 2016-04-22 | 2016-04-22 | |
| PCT/EP2017/059511 WO2017182625A1 (en) | 2016-04-22 | 2017-04-21 | Macrocyclic mcl1 inhibitors for treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2018008759A2 true CO2018008759A2 (es) | 2018-09-20 |
Family
ID=58664658
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2018/0008759A CO2018008759A2 (es) | 2016-04-22 | 2017-04-21 | Inhibidores de mcl-1 y métodos de uso de los mismos |
Country Status (37)
| Country | Link |
|---|---|
| US (4) | US9840518B2 (ru) |
| EP (1) | EP3445767B1 (ru) |
| JP (1) | JP6894449B2 (ru) |
| KR (1) | KR102388208B1 (ru) |
| CN (1) | CN109071566B (ru) |
| AR (1) | AR108301A1 (ru) |
| AU (1) | AU2017252222B2 (ru) |
| BR (1) | BR112018070677B1 (ru) |
| CA (1) | CA3020378A1 (ru) |
| CL (1) | CL2018002410A1 (ru) |
| CO (1) | CO2018008759A2 (ru) |
| CR (1) | CR20180499A (ru) |
| CY (1) | CY1123186T1 (ru) |
| DK (1) | DK3445767T3 (ru) |
| DO (1) | DOP2018000222A (ru) |
| EA (1) | EA036551B1 (ru) |
| ES (1) | ES2791319T3 (ru) |
| HR (1) | HRP20200673T1 (ru) |
| HU (1) | HUE049591T2 (ru) |
| IL (1) | IL262237B (ru) |
| LT (1) | LT3445767T (ru) |
| MA (1) | MA44721B1 (ru) |
| ME (1) | ME03729B (ru) |
| MX (1) | MX2018012711A (ru) |
| NI (1) | NI201800093A (ru) |
| PE (1) | PE20181803A1 (ru) |
| PH (1) | PH12018502227A1 (ru) |
| PL (1) | PL3445767T3 (ru) |
| PT (1) | PT3445767T (ru) |
| RS (1) | RS60257B1 (ru) |
| SG (1) | SG11201805838UA (ru) |
| SI (1) | SI3445767T1 (ru) |
| SV (1) | SV2018005742A (ru) |
| TN (1) | TN2018000319A1 (ru) |
| TW (1) | TWI742074B (ru) |
| WO (1) | WO2017182625A1 (ru) |
| ZA (1) | ZA201807766B (ru) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11708391B2 (en) | 2016-02-04 | 2023-07-25 | The Johns Hopkins University | Rapaglutins, novel inhibitors of GLUT and use thereof |
| CN108697701B (zh) | 2016-02-04 | 2021-10-26 | 约翰霍普金斯大学 | 平衡型核苷转运蛋白1的抑制剂Rapadocin及其用途 |
| US11066416B2 (en) | 2016-02-04 | 2021-07-20 | The Johns Hopkins University | Rapafucin derivative compounds and methods of use thereof |
| KR102388208B1 (ko) | 2016-04-22 | 2022-04-18 | 아스트라제네카 아베 | 암을 치료하기 위한 거대 환형 mcl1 억제제 |
| EP3458459B1 (en) | 2016-05-19 | 2022-04-27 | Bayer Aktiengesellschaft | Macrocyclic indole derivatives |
| TW201904976A (zh) * | 2017-03-31 | 2019-02-01 | 瑞典商阿斯特捷利康公司 | Ｍｃｌ-１抑制劑及其使用方法 |
| TWI781996B (zh) * | 2017-03-31 | 2022-11-01 | 瑞典商阿斯特捷利康公司 | 合成ｍｃｌ-１抑制劑之方法 |
| US10676485B2 (en) | 2017-08-15 | 2020-06-09 | Abbvie Inc. | Macrocyclic MCL-1 inhibitors and methods of use |
| CA3073108A1 (en) * | 2017-08-15 | 2019-02-21 | Abbvie Inc. | Macrocyclic mcl-1 inhibitors and methods of use |
| WO2019096914A1 (en) * | 2017-11-17 | 2019-05-23 | Bayer Aktiengesellschaft | Macrocyclic chlorine substituted indole derivatives |
| US11286263B2 (en) | 2017-11-17 | 2022-03-29 | The Broad Institute, Inc. | Macrocyclic fluorine substituted indole derivatives |
| TW201932473A (zh) | 2017-11-17 | 2019-08-16 | 美商博德研究所有限公司 | 巨環吲哚衍生物 |
| EP3710451A1 (en) | 2017-11-17 | 2020-09-23 | Bayer Aktiengesellschaft | Substituted macrocyclic indole derivatives |
| WO2019096907A1 (en) * | 2017-11-17 | 2019-05-23 | Bayer Aktiengesellschaft | Aryl annulated macrocyclic indole derivatives |
| UY37972A (es) * | 2017-11-17 | 2019-06-28 | Bayer Pharma AG | Derivados de indol macrocíclicos sustituidos con cloro |
| TW202014184A (zh) | 2018-04-30 | 2020-04-16 | 瑞典商阿斯特捷利康公司 | 用於治療癌症之組合 |
| AU2019347963A1 (en) * | 2018-09-30 | 2021-05-27 | Jiangsu Hengrui Medicine Co., Ltd. | Indole macrocyclic derivative, preparation method therefor and application thereof in medicine |
| TW202344250A (zh) | 2018-11-14 | 2023-11-16 | 瑞典商阿斯特捷利康公司 | 治療癌症之方法 |
| CN111205309B (zh) * | 2018-11-21 | 2023-04-07 | 江苏恒瑞医药股份有限公司 | 吲哚类大环衍生物、其制备方法及其在医药上的应用 |
| US11691989B2 (en) | 2018-11-22 | 2023-07-04 | Ascentage Pharma (Suzhou) Co., Ltd. | Macrocyclic indoles as Mcl-1 inhibitors |
| EP3781575A4 (en) * | 2019-01-23 | 2021-06-02 | Ascentage Pharma (Suzhou) Co., Ltd. | MACROCYCLIC FUSION PYRRAZOLES USED AS MCL-1 INHIBITORS |
| SG11202109367WA (en) * | 2019-03-08 | 2021-09-29 | Zeno Management Inc | Macrocyclic compounds |
| CN113574058B (zh) * | 2019-04-30 | 2024-04-16 | 江苏恒瑞医药股份有限公司 | 吲哚类大环衍生物、其制备方法及其在医药上的应用 |
| US20230081720A1 (en) | 2019-05-20 | 2023-03-16 | Novartis Ag | Mcl-1 inhibitor antibody-drug conjugates and methods of use |
| KR20220024694A (ko) * | 2019-06-21 | 2022-03-03 | 얀센 파마슈티카 엔.브이. | Mcl-1의 거대환식 억제제 |
| KR20220034136A (ko) | 2019-07-09 | 2022-03-17 | 얀센 파마슈티카 엔.브이. | Mcl-1 억제제로서의 거대환식 스피로사이클 유도체 |
| US20220372014A1 (en) * | 2019-10-01 | 2022-11-24 | The Johns Hopkins University | Neuroprotective compounds and methods of use thereof |
| WO2021092053A1 (en) * | 2019-11-08 | 2021-05-14 | Unity Biotechnology, Inc. | Mcl-1 inhibitor macrocycle compounds for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer |
| WO2021092061A1 (en) * | 2019-11-08 | 2021-05-14 | Unity Biotechnology, Inc. | Combination treatment for senescence-associated diseases |
| CA3157590A1 (en) | 2019-11-21 | 2021-05-27 | Janssen Pharmaceutica Nv | Macrocyclic sulfonyl derivatives as mcl-1 inhibitors |
| WO2021099579A1 (en) | 2019-11-21 | 2021-05-27 | Janssen Pharmaceutica Nv | Macrocyclic indole derivatives as mcl-1 inhibitors |
| BR112022012136A2 (pt) * | 2019-12-18 | 2022-08-30 | Zeno Man Inc | Compostos macrocíclicos |
| CN115151551A (zh) | 2020-02-21 | 2022-10-04 | 詹森药业有限公司 | 作为mcl-1抑制剂的大环吲哚衍生物 |
| TW202144368A (zh) * | 2020-03-30 | 2021-12-01 | 大陸商江蘇恒瑞醫藥股份有限公司 | 吲哚類大環衍生物的結晶形式及其製備方法 |
| US20230265105A1 (en) * | 2020-05-29 | 2023-08-24 | Janssen Pharmaceutica Nv | Macrocyclic 7-pyrazol-5-yl-indole derivatives as inhibitors of mcl-1 |
| KR20230026357A (ko) | 2020-06-19 | 2023-02-24 | 얀센 파마슈티카 엔.브이. | Mcl-1의 억제제로서의 n-연결된 마크로사이클릭 7-(피라졸-5-일)-인돌 유도체 |
| CN115943146A (zh) | 2020-06-19 | 2023-04-07 | 詹森药业有限公司 | N-连接的大环4-(吡唑-5-基)-吲哚衍生物作为mcl-1抑制剂 |
| WO2022008674A1 (en) | 2020-07-08 | 2022-01-13 | Janssen Pharmaceutica Nv | Macrocyclic ether containing indole derivatives as inhibitors of mcl-1 |
| WO2022032284A1 (en) * | 2020-08-07 | 2022-02-10 | Zeno Management, Inc. | Macrocyclic compounds |
| CN117136076A (zh) | 2020-11-24 | 2023-11-28 | 诺华股份有限公司 | Mcl-1抑制剂抗体药物缀合物和使用方法 |
| EP4008324A1 (en) | 2020-12-07 | 2022-06-08 | Cellestia Biotech AG | Combinations comprising an inhibitor of an anti-apoptotic protein, such as bcl-2, bcl-xl, bclw or mcl-1, and a notch signaling pathway inhibitor for treating cancer |
| EP4263556A1 (en) | 2020-12-17 | 2023-10-25 | JANSSEN Pharmaceutica NV | Branched macrocyclic 4-(pyrazol-5-yl)-indole derivatives as inhibitors of mcl-1 |
| KR20230145079A (ko) | 2021-02-12 | 2023-10-17 | 얀센 파마슈티카 엔브이 | 암의 치료를 위한 mcl-1 억제제로서의 마크로사이클릭1,3-브릿지된 6-클로로-7-피라졸-4-일-1h-인돌-2-카르복실레이트 및 6-클로로-7-피리미딘-5-일-1h-인돌-2-카르복실레이트 유도체 |
| WO2022251247A1 (en) * | 2021-05-28 | 2022-12-01 | Zeno Management, Inc. | Macrocyclic compounds |
| TW202315637A (zh) | 2021-06-11 | 2023-04-16 | 美商基利科學股份有限公司 | Mcl-1抑制劑與抗癌劑之組合 |
| JP2024521947A (ja) | 2021-06-11 | 2024-06-04 | ギリアード サイエンシーズ， インコーポレイテッド | Ｍｃｌ－１阻害剤と抗体薬物コンジュゲートとの組み合わせ |
| CN115490708A (zh) * | 2021-06-18 | 2022-12-20 | 苏州亚盛药业有限公司 | 磺酰胺类大环衍生物及其制备方法和用途 |
| WO2023057484A1 (en) | 2021-10-06 | 2023-04-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting and improving the efficacy of mcl-1 inhibitor therapy |
| TW202408588A (zh) | 2022-05-20 | 2024-03-01 | 瑞士商諾華公司 | 抗體-藥物結合物抗腫瘤化合物及其使用方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008131000A2 (en) * | 2007-04-16 | 2008-10-30 | Abbott Laboratories | 7-substituted indole mcl-1 inhibitors |
| US7981888B2 (en) | 2007-04-16 | 2011-07-19 | Abbott Laboratories | 1-oxyalkyl-2-carboxyl-7-nonsubstituted indole derivatives |
| CN102325787B (zh) * | 2008-12-22 | 2014-05-28 | 丘比斯特药物股份有限公司 | 治疗革兰氏阳性感染的新的抗菌剂 |
| UY33110A (es) * | 2009-12-23 | 2011-07-29 | Ironwood Pharmaceuticals Inc | Moduladores de CRTH2 |
| EP2710018B8 (en) * | 2011-05-19 | 2022-02-23 | Fundación del Sector Público Estatal Centro Nacional de Investigaciones Oncológicas Carlos III (F.S.P. CNIO) | Macrocyclic compounds as protein kinase inhibitors |
| US10093640B2 (en) | 2012-09-21 | 2018-10-09 | Vanderbilt University | Substituted benzofuran, benzothiophene and indole MCL-1 inhibitors |
| CA2922341C (en) | 2013-08-28 | 2022-06-07 | Vanderbilt University | Substituted indole mcl-1 inhibitors |
| WO2015123230A1 (en) * | 2014-02-12 | 2015-08-20 | Bristol-Myers Squibb Company | Benzothiazole macrocycles as inhibitors of human immunodeficiency virus replication |
| EP3122353B1 (en) | 2014-03-27 | 2020-10-28 | Vanderbilt University | Substituted indole mcl-1 inhibitors |
| US9963464B2 (en) * | 2014-04-11 | 2018-05-08 | Bayer Pharma Aktiengesellschaft | Macrocyclic compounds |
| US9949965B2 (en) | 2014-10-17 | 2018-04-24 | Vanderbilt University | Tricyclic indole Mcl-1 inhibitors and uses thereof |
| KR102388208B1 (ko) | 2016-04-22 | 2022-04-18 | 아스트라제네카 아베 | 암을 치료하기 위한 거대 환형 mcl1 억제제 |
-
2017
- 2017-04-21 KR KR1020187033540A patent/KR102388208B1/ko active IP Right Grant
- 2017-04-21 BR BR112018070677-9A patent/BR112018070677B1/pt active IP Right Grant
- 2017-04-21 MA MA44721A patent/MA44721B1/fr unknown
- 2017-04-21 ES ES17720720T patent/ES2791319T3/es active Active
- 2017-04-21 EA EA201892300A patent/EA036551B1/ru not_active IP Right Cessation
- 2017-04-21 PE PE2018001558A patent/PE20181803A1/es unknown
- 2017-04-21 US US15/493,210 patent/US9840518B2/en active Active
- 2017-04-21 CN CN201780022366.0A patent/CN109071566B/zh active Active
- 2017-04-21 AR ARP170101026A patent/AR108301A1/es unknown
- 2017-04-21 TW TW106113380A patent/TWI742074B/zh active
- 2017-04-21 WO PCT/EP2017/059511 patent/WO2017182625A1/en active Application Filing
- 2017-04-21 SI SI201730246T patent/SI3445767T1/sl unknown
- 2017-04-21 CR CR20180499A patent/CR20180499A/es unknown
- 2017-04-21 SG SG11201805838UA patent/SG11201805838UA/en unknown
- 2017-04-21 ME MEP-2020-99A patent/ME03729B/me unknown
- 2017-04-21 EP EP17720720.6A patent/EP3445767B1/en active Active
- 2017-04-21 JP JP2018553226A patent/JP6894449B2/ja active Active
- 2017-04-21 PL PL17720720T patent/PL3445767T3/pl unknown
- 2017-04-21 PT PT177207206T patent/PT3445767T/pt unknown
- 2017-04-21 DK DK17720720.6T patent/DK3445767T3/da active
- 2017-04-21 LT LTEP17720720.6T patent/LT3445767T/lt unknown
- 2017-04-21 CA CA3020378A patent/CA3020378A1/en active Pending
- 2017-04-21 CO CONC2018/0008759A patent/CO2018008759A2/es unknown
- 2017-04-21 RS RS20200549A patent/RS60257B1/sr unknown
- 2017-04-21 AU AU2017252222A patent/AU2017252222B2/en active Active
- 2017-04-21 TN TNP/2018/000319A patent/TN2018000319A1/en unknown
- 2017-04-21 MX MX2018012711A patent/MX2018012711A/es unknown
- 2017-04-21 HU HUE17720720A patent/HUE049591T2/hu unknown
- 2017-10-23 US US15/790,660 patent/US10196404B2/en active Active
-
2018
- 2018-08-23 CL CL2018002410A patent/CL2018002410A1/es unknown
- 2018-09-12 SV SV2018005742A patent/SV2018005742A/es unknown
- 2018-09-25 NI NI201800093A patent/NI201800093A/es unknown
- 2018-10-05 DO DO2018000222A patent/DOP2018000222A/es unknown
- 2018-10-09 IL IL262237A patent/IL262237B/en unknown
- 2018-10-18 PH PH12018502227A patent/PH12018502227A1/en unknown
- 2018-11-19 ZA ZA2018/07766A patent/ZA201807766B/en unknown
- 2018-12-18 US US16/223,538 patent/US10889594B2/en active Active
-
2020
- 2020-04-28 HR HRP20200673TT patent/HRP20200673T1/hr unknown
- 2020-05-14 CY CY20201100443T patent/CY1123186T1/el unknown
- 2020-12-04 US US17/111,896 patent/US11472816B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2018008759A2 (es) | Inhibidores de mcl-1 y métodos de uso de los mismos | |
| NI201900070A (es) | Compuestos heterocíclicos como inmunomoduladores | |
| CL2019001077A1 (es) | Derivados de 6,7,8,9-tetrahidro-3h-pirazolo[4,3-f] isoquinolina útiles en el tratamiento del cáncer. | |
| DOP2016000299A (es) | Derivados de pirrolidina-2,5-diona, composiciones farmacéuticas y su uso como inhibidores ido1 | |
| CL2018003701A1 (es) | Compuestos heterocíclicos como inmunomoduladores. | |
| NI201700020A (es) | Compuestos de aminopirimidinilo como inhibidores de jak | |
| CL2020001218A1 (es) | Compuestos útiles para inhibir a cdk7. | |
| DOP2017000151A (es) | Derivados de quinazolina utilizados para tratar el vih | |
| NI201600165A (es) | Inhibidores de desmetilasa 1 específica a lisina | |
| BR112016016844A2 (pt) | Compostos heterocíclicos | |
| CU20200051A7 (es) | Componentes heterocíclicos bicíclicos sustituidos como inhibidores de prmt5 | |
| CO2018000589A2 (es) | Oxiesteroles y composiciones farmacéuticas que los contienen | |
| UY34888A (es) | Inhibidores del virus de la hepatitis c | |
| NZ726608A (en) | Phosphatidylinositol 3-kinase inhibitors | |
| BR112018070123A2 (pt) | oxiesterós e métodos de uso dos mesmos | |
| CU20180019A7 (es) | Derivados de heteroarilo como inhibidores de parp | |
| NZ726360A (en) | Phosphatidylinositol 3-kinase inhibitors | |
| DOP2021000017A (es) | Compuestos de pirimidina y composiciones farmaceuticas para prevenir o tratar cánceres que incluyen los mismos | |
| CO2019009722A2 (es) | Dendrímeros terapéuticos | |
| AR102981A1 (es) | Inhibidores de la necrosis celular y métodos de preparación de los mismos | |
| ECSP19051352A (es) | Inhibidores selectivos de jak1 | |
| CL2018003121A1 (es) | Inhibidores del potenciador del homólogo zeste 2. | |
| CO2021007172A2 (es) | Sales cristalinas de un inhibidor de calicreína plasmática | |
| AR105400A1 (es) | Inhibidores de jak1 | |
| SV2016005317A (es) | Derivados de pirrolidina -2,5-diona, composiciones farmacéuticas y métodos para usar como inhibidores ido1 |